COMP <GO>
INM vs MBRX // EV/EBITDA & P/E VALUATION
InMed Pharmaceuticals Inc. (NASDAQ) VS. Moleculin Biotech Inc. (NASDAQ) • 15-METRIC TALLY: INM 2
— MBRX 1
■ METRIC PARITY
LAST: $1.63 (+1.61%) • MKT CAP: $8.9M
valuation
—
LAST: $8.72 (-0.29%) • MKT CAP: $9.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INM VS. MBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INM | MBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 34.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 7.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | INM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.8 | 44.6 | +25.23 | INM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.9M | $9.2M | -$228.7K | MBRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INM REV | MBRX REV | INM GROSS % | MBRX GROSS % | INM FCF | MBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.9M | $0 | 34.5% | — | -$8.1M | -$22.7M |
| FY 2024 | $4.6M | $0 | 23.9% | — | -$7.0M | -$23.9M |
| FY 2023 | $4.1M | $0 | — | — | -$7.3M | -$23.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INM // BETA —
MBRX // BETA —